Spinogenix’s Daily Pill SPG302 Receives FDA IND Nod for ALS Treatment
FDA grants orphan designation to Fragile X syndrome therapeutic
Spinogenix’s SPG601 Earns Orphan Drug Designation for Fragile X Syndrome
FDA clears Phase 2 trial of oral SPG601 in men with fragile X
FDA clears investigational new drug application for Fragile X treatment
Two major breakthroughs in Fragile X Syndrome treatments
Spinogenix’s Investigational New Drug Application for Novel Treatment for Fragile X Syndrome Cleared to Begin Phase II Trial
A Promising Treatment for MND
A new drug that could reverse the worst symptoms of MND is about to be trialled in Australia.
Novel motor neurone disease, MND, drug SPG302 to be trialled in Australia
In the News Trials to start of daily pill for MND that could reverse condition February 18, 2024 (HERALD SUN AUSTRALIA) By Sarah Booth— Australian motor neurone disease patients will be the first in the world to trial a “novel” treatment that scientists hope could not only slow — but actually reverse — the condition. […]
